MICHAEL SHEEHAN: Open Payments
NPI 1528060597 · TAMPA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,852 in 61 payments from 19 companies in 2025. Trend: 2023 $2,035 · 2024 $1,948 · 2025 $1,852
Food & beverage: $1,852
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $250 |
| Noven Therapeutics, LLC | 9 | $214 |
| Indivior Inc. | 5 | $199 |
| Neurocrine BioSciences, Inc. | 3 | $167 |
| Lundbeck LLC | 5 | $165 |
| Teva Pharmaceuticals USA, Inc. | 3 | $163 |
| E.R. Squibb & Sons, L.L.C. | 2 | $118 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $81 |
| Janssen Pharmaceuticals, Inc | 3 | $69 |
| Alkermes, Inc. | 3 | $60 |
Products named: REXULTI, Xelstrym, SUBLOCADE, INGREZZA, AUSTEDO XR, COBENFY, CAPLYTA, SPRAVATO.
Industry payments across FL — which companies pay providers there.
